Effects of a urolith prevention diet on urine compositions of glycosaminoglycans, Tamm-Horsfall glycoprotein, and nephrocalcin in cats with calcium oxalate urolithiasis

Jody P. Lulich Minnesota Urolith Center, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN 55108

Search for other papers by Jody P. Lulich in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Carl A. Osborne Minnesota Urolith Center, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN 55108

Search for other papers by Carl A. Osborne in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Mauricio Carvalho Departmento de Clinica Medica, Hospitlas de Clinicas, Universidad Federal do Parana, Curitiba, PR, Brazil

Search for other papers by Mauricio Carvalho in
Current site
Google Scholar
PubMed
Close
 MD
, and
Yasushi Nakagawa Department of Biochemistry and Molecular Biology and the Department of Medicine, Biological Sciences Division, University of Chicago, Chicago, IL 60637.

Search for other papers by Yasushi Nakagawa in
Current site
Google Scholar
PubMed
Close
 PhD

Abstract

Objective—To evaluate urine concentrations of glycosaminoglycans, Tamm-Horsfall glycoprotein, and nephrocalcin in cats fed a diet formulated to prevent calcium oxalate uroliths.

Animals—10 cats with calcium oxalate urolithiasis.

Procedures—In a previous study conducted in accordance with a balanced crossover design, cats were sequentially fed 2 diets (the diet each cat was consuming prior to urolith detection and a diet formulated to prevent calcium oxalate uroliths). Each diet was fed for 8 weeks. At the end of each 8-week period, a 72-hour urine sample was collected. Concentrations of glycosaminoglycans, Tamm-Horsfall glycoprotein, and the 4 isoforms of nephrocalcin in urine samples collected during that previous study were measured in the study reported here.

Results—Diet had no effect on the quantity of Tamm-Horsfall glycoprotein and nephrocalcin in urine. However, the urine concentration of glycosaminoglycans was significantly higher during consumption of the urolith prevention diet.

Conclusions and Clinical Relevance—Feeding a urolith prevention diet increased the urine concentration of glycosaminoglycans, which are glycoprotein inhibitors of growth and aggregation of calcium oxalate crystals.

Abstract

Objective—To evaluate urine concentrations of glycosaminoglycans, Tamm-Horsfall glycoprotein, and nephrocalcin in cats fed a diet formulated to prevent calcium oxalate uroliths.

Animals—10 cats with calcium oxalate urolithiasis.

Procedures—In a previous study conducted in accordance with a balanced crossover design, cats were sequentially fed 2 diets (the diet each cat was consuming prior to urolith detection and a diet formulated to prevent calcium oxalate uroliths). Each diet was fed for 8 weeks. At the end of each 8-week period, a 72-hour urine sample was collected. Concentrations of glycosaminoglycans, Tamm-Horsfall glycoprotein, and the 4 isoforms of nephrocalcin in urine samples collected during that previous study were measured in the study reported here.

Results—Diet had no effect on the quantity of Tamm-Horsfall glycoprotein and nephrocalcin in urine. However, the urine concentration of glycosaminoglycans was significantly higher during consumption of the urolith prevention diet.

Conclusions and Clinical Relevance—Feeding a urolith prevention diet increased the urine concentration of glycosaminoglycans, which are glycoprotein inhibitors of growth and aggregation of calcium oxalate crystals.

Contributor Notes

Supported in part by an educational grant from Hill's Pet Nutrition Incorporated.

Address correspondence to Dr. Lulich (lulic001@umn.edu).
  • 1.

    Ljunghall S. Incidence of renal stones in Western countries. In: Schwille PO, Smith LH, Robertson WG, eds. Urolithiasis and related clinical research. New York: Plenum Press, 1984;31.

    • Search Google Scholar
    • Export Citation
  • 2.

    Ross SJ, Osborne CA, Lulich JP, et al. Canine and feline nephrolithiasis. Epidemiology, detection and management. Vet Clin North Am Small Anim Pract 1999; 29:231250.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Cannon AB, Westropp JL, Ruby AL, et al. Evaluation of trends in urolith composition in cats: 5,230 cases (1985–2004). J Am Vet Med Assoc 2007; 231:570576.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Osborne CA, Lulich JP, Kruger JM, et al. Analysis of 451,891 canine uroliths, feline uroliths, and feline urethral plugs from 1981to 2007: perspectives from the Minnesota Urolith Center. Vet Clin North Am Small Anim Pract 2009; 39:183197.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Hess B, Kok DJ. Nucleation, growth, and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, et al, eds. Kidney stones: medical and surgical management. Philadelphia: Lippincott-Raven, 1996;332.

    • Search Google Scholar
    • Export Citation
  • 6.

    Werness PG, Brown CM, Smith LH, et al. Equil 2: a basic computer program for the calculation of urinary saturation. J Urol 1985; 134:12421244.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Cao LC, Boevé ER, Schröder FH, et al. The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration. J Urol 1992; 147:16431646.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Hess B, Nakagawa Y, Parks JH, et al. Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 1991; 260:F569F578.

    • Search Google Scholar
    • Export Citation
  • 9.

    Coe FL, Parks JH & Nakagawa Y. Inhibitors and promoters of calcium oxalate crystallization. In: Coe FL, Favus MJ, Pak CY, et al, eds. Disorders of bone and mineral metabolism. Philadelphia: Lippincott-Raven, 1991;757799.

    • Search Google Scholar
    • Export Citation
  • 10.

    Min W, Shiraga H, Chalko C, et al. Quantitative studies of human urinary excretion of uropontin. Kidney Int 1998; 53:189193.

  • 11.

    Stapleton AM, Ryall RL. Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. Br J Urol 1995; 75:712719.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Lulich JP, Osborne CA, Lekcharoensuk C, et al. Effect of diet on urine composition of cats with calcium oxalate urolithiasis. J Am Anim Hosp Assoc 2004; 40:185191.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Jones B, Kenward MG. Design and analysis of cross-over trials. 2nd ed. Boca Rotan, Fla: Chapman and Hall/CRC Press, 2003;114146.

  • 14.

    Peterson GL. Determination of total protein. Methods Enzymol 1983; 91:95119.

  • 15.

    Fellstrom B, Danielson BG, Lind E, et al. Enzymatic determination of urinary chondroitin sulphate: applications in renal stone disease and acromegaly. Eur J Clin Invest 1986; 16:292296.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Serafini-Cessi F, Bellabarba G, Malagolini N, et al. Rapid isolation of Tamm-Horsfall glycoprotein from human urine. J Immunol Methods 1989; 120:185189.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Nakagawa Y, Ahmed M, Hall SL, et al. Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. J Clin Invest 1987; 79:17821787.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Nakagawa Y, Abram V, Parks JH, et al. Urine glycoprotein crystal growth inhibitors: evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J Clin Invest 1985; 76:14551462.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Caudarella R, Stefani F, Rizzoli E, et al. Preliminary results of glycosaminoglycan excretion in normal and stone forming subjects: relationship with uric acid excretion. J Urol 1983; 129:665667.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Hwang TI, Preminger GM, Poindexter J, et al. Urinary glycosaminoglycans in normal subjects and patients with stones. J Urol 1988; 139:995997.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Michelacci YM, Glashan RQ & Schor N. Urinary excretion of glycosaminoglycans in normal and stone forming subjects. Kidney Int 1989; 36:10221028.

  • 22.

    Nikkilä MT. Urinary glycosaminoglycan excretion in normal and stone-forming subjects: significant disturbance in recurrent stone formers. Urol Int 1989; 44:157159.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Erickson DR, Sheylkhnazan M, Bhvanandan VP. Molecular size affects urine excretion of pentosan polysulfate. J Urol 2006; 175:11431147.

  • 24.

    Scurr DS, Robertson WG. Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in artificial urine. J Urol 1986; 136:128131.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Grases F, Llompart I, Conte A, et al. Glycosaminoglycans and oxalocalcic urolithiasis. Nephron 1994; 68:449453.

  • 26.

    Nesse A, Garbossa G, Romero MC. Glycosaminoglycan in urolithiasis. Nephron 1992; 62:3639.

  • 27.

    Rhodes DC, Hinsman EJ, Rhodes JA, et al. Urinary Tamm-Hors-fall glycoprotein concentrations in normal and urolithiasis-affected male cats determined by an ELISA. Zentralbl Veterinarmed A 1992; 39:621634.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Jaggi M, Nakagawa Y, Zipperle I, et al. Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function. Urol Res 2007; 35:5562.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Nakagawa Y. Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion. Keio J Med 1997; 46:19.

  • 30.

    Carvalho M, Lulich JP, Osborne CA, et al. Defective urinary crystallization inhibition and urinary stone formation. Int Braz J Urol 2006; 32:342349.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Kurutz JW, Carvalho M & Nakagawa Y. Nephrocalcin isoforms coat crystal surfaces and differentially affect calcium oxalate monohydrate crystal morphology, growth, and aggregation. J Crystal Growth 2003; 255:392402.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Mustafi D, Nakagawa Y, Makinen MW. ENDOR studies of VO2+: probing proton-metal ion interactions in nephrocalcin. Cell Mol Biol 2000; 46:13451360.

    • Search Google Scholar
    • Export Citation

Advertisement